Inventiva S.A. (FRA:6IV)

Market Cap	712.44M +86.2%
Revenue (ttm)	6.76M -52.0%
Net Income	-354.14M
EPS	-1.90
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	750
Open	4.025
Previous Close	3.990
Day's Range	4.025 - 4.200
52-Week Range	2.460 - 5.810
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 25, 2026

About Inventiva

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-β, a pre-clinical program for the tr...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Employees: 73
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6IV

Financial Performance

In 2025, Inventiva's revenue was 6.76 million, a decrease of -52.03% compared to the previous year's 14.10 million. Losses were -354.14 million, 92.2% more than in 2024.